14-Aug-2026
Centrum Reframes Healthy Aging as a Proactive Practice for Adults 35 and Beyond
Business Wire (Thu, 13-Aug 3:00 PM ET)
Haleon’s New Gum-Health Toothpaste Trial: What Investors Should Watch
TipRanks (Wed, 12-Aug 12:31 PM ET)
Haleon plc: Cash tender offer for outstanding 2027 3.375% Fixed Rate Notes
PRNewswire (Tue, 11-Aug 8:49 AM ET)
Business Wire (Thu, 6-Aug 9:00 AM ET)
Sensodyne’s ‘World’s Coldest Treat’ Pop-Up Highlights HLN’s Focus on Everyday Oral Health Solutions
Market Chameleon (Thu, 6-Aug 4:21 AM ET)
Business Wire (Wed, 5-Aug 5:04 PM ET)
Haleon Canada Appoints Daniela Cavinatto as General Manager
Globe Newswire (Tue, 4-Aug 9:00 AM ET)
Haleon to Accelerate AI-powered Transformation With New Five-year Microsoft Collaboration
Business Wire (Wed, 1-Jul 5:00 AM ET)
Business Wire (Fri, 26-Jun 4:00 AM ET)
Advil Challenges Sports Culture's "No Pain No Gain" Mentality This Summer
Business Wire (Tue, 9-Jun 7:00 AM ET)
Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.
Haleon PLC American Depositary Shares (Each Representing Two Ordinary Shares) trades on the NYSE stock market under the symbol HLN.
As of August 14, 2026, HLN stock price declined to $9.70 with 3,132,675 million shares trading.
HLN has a beta of 0.03, meaning it tends to be less sensitive to market movements. HLN has a correlation of 0.00 to the broad based SPY ETF.
HLN has a market cap of $42.75 billion. This is considered a Large Cap stock.
In the last 3 years, HLN traded as high as $11.42 and as low as $7.70.
The top ETF exchange traded funds that HLN belongs to (by Net Assets): PPH, QLTI, AVDE, FENI, YLDE.
HLN has underperformed the market in the last year with a price return of +3.2% while the SPY ETF gained +21.5%. However, in the short term, HLN had mixed performance relative to the market. It has outperformed in the last 3 months, returning +9.6% vs +4.0% return in SPY. But in the last 2 weeks, HLN shares have been beat by the market, returning -1.1% compared to an SPY return of +3.9%.
HLN support price is $9.58 and resistance is $9.89 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that HLN shares will trade within this expected range on the day.